[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619985":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":34,"centralContacts":38,"locations":44,"responsibleParty":61,"collaborators":34,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":34,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":34,"overallStatus":47,"whyStopped":34,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Joincare Pharmaceutical Group Industry Co., Ltd","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"dose1 of JKN2403 Tablets, once daily orally","EXPERIMENTAL","dose1 of JKN2403 Tablets once daily orally, for 24 weeks",[13],"Drug: JKN2403 Tablets",{"label":15,"type":10,"description":16,"interventionNames":17},"dose2 of JKN2403 Tablets once daily orally","dose2 of JKN2403 Tablets once daily orally, for 24 weeks",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"dose3 of JKN2403 Tablets once daily","dose3 of JKN2403 Tablets once daily orally, for 24 weeks",[13],{"label":23,"type":24,"description":25,"interventionNames":26},"Placebo once daily","PLACEBO_COMPARATOR","Placebo once daily orally, for 24 weeks",[27],"Drug: Placebo",[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","JKN2403 Tablets","JKN2403 Tablets once daily orally, for 24 weeks",[9,15,19],null,{"type":30,"name":36,"description":36,"armGroupLabels":37,"otherNames":34},"Placebo",[23],[39],{"name":40,"role":41,"phone":42,"phoneExt":34,"email":43},"Weijie Guan Professor","CONTACT","020-81566265","battery203@163.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":34,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"The First Affiliated Hospital of Guangzhou Medical University","RECRUITING","Guangzhou","Guangdong","China","CN",{"type":53,"coordinates":54},"Point",[55,56],113.25,23.11667,{"lat":56,"lon":55},[59],{"name":40,"role":41,"phone":60,"phoneExt":34,"email":43},"02081566265",{"type":62,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100619985","phase-2-a-phase-iia-randomized-double-blind-placebo-controlled-trial-of-jkn2403-in-copd-100619985",false,"NCT07351734","A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD","A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetic Characteristics of JKN2403 Tablets in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)","COPD","Inclusion Criteria:\n\n* Written informed consent; able and willing to comply with study procedures.\n* Adults with documented COPD diagnosis and medical history consistent with guideline criteria.\n* Relevant exposure history consistent with COPD (e.g., smoking).\n* On stable, guideline-based maintenance COPD therapy prior to randomization, per investigator judgment.\n* Protocol-defined exacerbation history, symptom burden, and lung function at screening.\n\nExclusion Criteria:\n\n* Current or past asthma, or other clinically significant respiratory disease that may confound assessment.\n* Clinically significant uncontrolled comorbidities that increase risk or interfere with participation\u002Foutcomes.\n* Immunodeficiency\u002Fimmune dysregulation, active autoimmune disease requiring systemic immunosuppression, or significant opportunistic infection history.\n* Active clinically significant infection or recent infection requiring systemic therapy; recent protocol-defined COPD exacerbation.\n* Current\u002Frecent malignancy (except low-risk, adequately treated cancers per protocol) or clinically significant abnormal screening labs.\n* Prohibited recent vaccines or therapies, prior relevant biologic\u002Ftargeted therapy exposure, severe hypersensitivity to biologics\u002FIMP, - pregnancy\u002Fbreastfeeding, or inability to comply (including substance abuse), per investigator judgment.","ALL","40 Years","80 Years",{"count":75,"type":76},120,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","The goal of this clinical trial is to learn if drug JKN2403 works to treat moderate-to-severe COPD in adults. It will also learn about the safety and pharmacokinetic characteristics of drug JKN2403. The main questions it aims to answer are:\n\nDoes drug JKN2403 reduce the incidence of AECOPD or improve the quality of life or alleviate symptoms related to COPD?\n\nResearchers will compare drug JKN2403 to a placebo (a look-alike substance that contains no drug) to see if drug JKN2403 works to treat moderate-to-severe COPD.\n\nParticipants will:\n\nTake drug JKN2403 or a placebo every day for 24 weeks Visit the clinic once every four weeks for checkups and tests Keep a diary of their symptoms and the number of times they use a rescue inhaler",[82],"COPD (Chronic Obstructive Pulmonary Disease)","2026-01-10",{"date":85,"type":86},"2026-01-20","ACTUAL",{"date":88,"type":86},"2025-11-06",{"date":90,"type":76},"2026-09-30",{"name":5,"class":6},1]